Suppr超能文献

在短期内,恢复甲状腺功能正常并不能改善亚临床甲状腺功能减退患者的心血管危险因素。

Restoration of euthyroidism does not improve cardiovascular risk factors in patients with subclinical hypothyroidism in the short term.

作者信息

Beyhan Z, Ertürk K, Uçkaya G, Bolu E, Yaman H, Kutlu M

机构信息

Department of Endocrinology and Metabolism, Gulhane School of Medicine, 06018 Etlik, Ankara, Turkey.

出版信息

J Endocrinol Invest. 2006 Jun;29(6):505-10. doi: 10.1007/BF03344139.

Abstract

Subclinical hypothyroidism (SH) is being accepted as a condition that is associated with increased risk of cardiovascular disease. Restoration of euthyroidism might be involved in prevention of cardiovascular disease. Thus, we evaluated biochemical risk factors of 75 patients with SH without evidence of any other diseases before and after restoration of euthyroidism and compared to 27 healthy controls. Before and a mean of 18.2+/-4.4 weeks after restoration of euthyroidism, serum total and LDL cholesterol, lipoprotein (Lp) (a), total homocysteine (t-Hyc) and highly sensitive C-reactive protein (hsCRP) levels were analyzed. Pre-treatment levels of TSH (10.04+/-5.36 vs 1.74+/-1.1 mIU/l, p<0.05), total cholesterol (204+/-68 vs 179+/-26 mg/dl, p<0.05) and LDL cholesterol (129+/-50 vs 106+/-16 mg/dl, p<0.05) were significantly higher than controls while Lp (a), t-Hyc, and hsCRP levels were not different. None of these biochemical risk factors have improved after euthyroidism in patients with SH with average dose of 85+/-30 microg/day, when compared to pre-treatment levels. Only in a subgroup of patients (no. 30) with higher TSH levels (>10 mIU/l), did serum LDL cholesterol levels decrease significantly (139+/-38 vs 112+/-35 mg/dl, p<0.05). Lp (a), t-Hyc and hsCRP levels were not significantly different after treatment with levothyroxine therapy even in this subgroup of patients. We conclude that clinical management of SH does not contribute to prevention of cardiovascular disease in the short term, and monitoring risk factors of cardiovascular disease does not offer additional benefits for treating patients with SH.

摘要

亚临床甲状腺功能减退(SH)被认为是一种与心血管疾病风险增加相关的病症。甲状腺功能正常的恢复可能参与心血管疾病的预防。因此,我们评估了75例无任何其他疾病证据的SH患者在甲状腺功能恢复正常前后的生化危险因素,并与27名健康对照进行比较。在甲状腺功能恢复正常前及恢复正常后平均18.2±4.4周,分析血清总胆固醇、低密度脂蛋白胆固醇、脂蛋白(Lp)(a)、总同型半胱氨酸(t-Hyc)和高敏C反应蛋白(hsCRP)水平。治疗前促甲状腺激素水平(10.04±5.36 vs 1.74±1.1 mIU/l, p<0.05)、总胆固醇(204±68 vs 179±26 mg/dl, p<0.05)和低密度脂蛋白胆固醇(129±50 vs 106±16 mg/dl, p<0.05)显著高于对照组,而Lp(a)、t-Hyc和hsCRP水平无差异。与治疗前水平相比,平均剂量为85±30μg/天的SH患者在甲状腺功能正常后,这些生化危险因素均未改善。仅在促甲状腺激素水平较高(>10 mIU/l)的患者亚组(30例)中,血清低密度脂蛋白胆固醇水平显著降低(139±38 vs 112±35 mg/dl, p<0.05)。即使在该患者亚组中,左甲状腺素治疗后Lp(a)、t-Hyc和hsCRP水平也无显著差异。我们得出结论,SH的临床管理在短期内无助于预防心血管疾病,监测心血管疾病危险因素对治疗SH患者没有额外益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验